Los Angeles Capital Management
ELVN icon

Los Angeles Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Los Angeles Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,409
Closed -$130K – 2459
2025
Q4 		$130K Buy
+5,409
New +$108K ﹤0.01% 1354

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Los Angeles Capital Management's ELVN Position: Q1 2026 in Review

Los Angeles Capital Management sold out of Enliven Therapeutics (ELVN) in Q1 2026, closing a stake of 5,409 shares — an estimated $130K sold.

Los Angeles Capital Management first reported a position in ELVN in Q4 2025 and held it in 1 quarter. The position peaked at $130K in Q4 2025. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Los Angeles Capital Management reported no remaining Enliven Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Los Angeles Capital Management sold 5,409 Enliven Therapeutics shares in Q1 2026, an estimated $130K.
  • Los Angeles Capital Management first reported a position in Enliven Therapeutics in Q4 2025 and held it in 1 quarter.
  • Los Angeles Capital Management's Enliven Therapeutics position peaked at $130K in Q4 2025.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.